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1 Introduction
Protracted periods of fetal tachyarrhythmia (su-
praventricular tachycardia, atrial flutter and atrial
fibrillation) may cause congestive heart failure
and fetal death in the presence of non-immune
hydrops fetalis. If there are contraindications to
immediate delivery, such as fetal immaturity,
transplacental therapy of the fetus can be achieved
by administering antiarrhythmic agents that can
cross the placenta to the mother. This has proven
to be successful in a number of cases [1, 2, 9, 11,
13].
Publications on fetal tachyarrhythmia and our
own observations show that, particularly in tachy-
arrhythmias with advanced states of non immune
hydrops fetalis, transplacental antiarrhythmic
therapy of the fetus produces either no or only
a temperary cardioversion in which the hydrops
fetalis remains constant or continues to increase.
In such fetal emergency conditions it seems advis-
able to give antiarrhythmic agents directly to the
fetus in addition to the transplacental route. In
the presence of marked ascites the intraperitoneal
administration of antiarrhythmic drugs using ul-
trasound monitoring is technically simple, can be
repeated and is most effective. This will be demon-
strated on the basis of the following two cases
with supraventricular tachycardia or atrial flutter,
both associated with severe hydrops fetalis.
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2 Case reports
Case 1: A 20-year-old gravida 2, para 1 in a
26 + 2 weeks gestation was referred because of
supraventricular tachycardia (SVT) with ascites
and polyhydramnios after an uneventful course
of pregnancy.
Sonographic findings: inactive fetus, constant
SVT about 250 bpm, non-immune hydrops fetalis
with severe ascites, severe polyhydramnios, nor-
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mal placenta (bipartietal diameter: 73 mm, fronto-
occipital diameter: 86 mm, abdominal transverse
diameter: 78 mm; heart (short axis at atrioventri-
cular valve level): 28 mm).
Therapy: Rapid digitalization with beta-methyldi-
goxin (digoxin level of January 31, February 3,
1986: 1.0 ng/ml). There was sustained SVT, in cre-
asing ascites (figure 1), presence of skin edema
and rapidly advancing pericardial effusion (figures
2 and 3) even after additional daily oral admini-
stration of 360 mg verapamil.
It was decided to administer antiarrhythmic ther-
apy directly to the fetus: from February 4, 1986
(72+2 weeks gestation) up to February 14, 1986
(28 + 5 weeks gestation) 12 intraperitoneal admin-
istrations of antiarrhythmic agents were carried
out (except for February 8, 12, and 13, 1986 in
the morning as well as in the evening) with the
Figure 1. Massive ascites in the 28th week of gestation
(transverse scan) (case 1).
Figure 3. Pericardial effusion in the 28th week of gesta-
tion (case 1) demonstrated by a M-mode echocardio-
gram across both ventricular chambers the level of the
chordae tendineae (Figures 1 — 3 from GEMBRUCH U, M
HANSMANN, DA REDEL, R BALD: Ultraschall Klin Prax
2 (1987) 33).
Figure 2. Cardiac four-chamber view with pericardial
effusion in the 28th week of gestation (case 1).
following doses being used: 10 g betamethyldi-
goxin and 1 mg verapamil, and, in the last 4
punctures, an additional 7-10 mg propafenon.
Within 5-15 minutes after these interventions
cardioversion with sinus rhythm of 150 bpm was
established, lasting a few hours, max. 36 hours.
The digoxin concentration measured in the ascites
fluid prior to the administration of drugs was
between 0.6 ng/ml and 1.0 ng/ml. During this time
the fetus became active again; in the meantime
the maternal digoxin level could be increased to
values between 1.4 ng/ml and 1.6 ng/ml; starting
on January 12, 1986 the mother was given an
additional 450 mg propafenon daily along with
methyldigoxin and verapamil together with main-
tenance therapy of 400 g betamethyldigoxin.
From February 15, 1986 (28 + 2 weeks gestation)
a constant sinus rhythm was recorded following
oral medication (300 g betamethyldigoxin, 360 g
verapamil and 450 mg propafenon daily). A fur-
ther increase in the dose of digitalis was not pos-
sible due to maternal signs of toxicity (first-degree
AV-block, nausea, vomiting); there was no evi-
dence of pericardial effusion on February 21,1986
(29 + 5 weeks gestation), the ascites decreased
slowly and had disappeared by the time of out-
patient monitoring on March 26, 1986 (34 + 3
weeks gestation). On April 10, 1986 (36 + 5 weeks
gestation) there was a spontaneous vaginal deliv-
ery: female infant 3080 grams, 50 cms long. Apgar
score: 8/7/9 at 1, 5 and 10 minutes. After delivery
the arrhythmia dit not reoccur even though the
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antiarrhythmic therapy was discontinued. The
child was treated with phenobarbital because of
suspected seizures occuring twice in the neonatal
period but is otherwise in good condition and has
developed appropriately by age.
Case 2: A 23 year-old gravida 2, para 1, during the
33th week of gestation was admitted on August
29, 1986 because of bradyarrhythmia and non-
immune hydrops fetalis with ascites and skin ed-
ema, cardiomegaly and a hydropic placenta.
Sonographic findings include: immobile fetus,
atrial nutter at 300 to 350 bpm with 1 : 1 AV-
conduction and periodic 2: 1 AV-block; non-im-
mune hydrops fetalis with massive ascites and
slight skin edema, cardiomegaly, dilated veins,
hepatomegaly, normal volume of amniotic fluid,
slightly hydropic placenta (biparietal diameter: 90
mm, fronto-occipital diameter: 73 mm, abdominal
transverse diameter: max. 130 mm; heart (short
axis at AV-valve level): 60 mm).
Pulsed and 2-dimensional color Doppler-echocar-
diography showed severe regurgitation of the mi-
tral and tricuspidal valves, possibly as a conse-
quence of the pronounced dilatation of the cardiac
structure.
Therapy: Rapid digitalization of the mother with
betamethyldigoxin and additional daily oral ad-
ministration of 900 mg propafenon (maternal di-
goxin level: on August 30, 1986: 1.6 ng/ml, on
September 1, 1986: 2.7 ng/ml and on September
4, 1986: 1.6 ng/ml); because of the poor condition
of the fetus it was decided to treat it directly. On
August 30, 1986 150 ml of ascites was aspirated
and intraperitoneal instillation of 18 g betame-
thyldigoxin and 2 mg propafenon was performed.
Eight minutes later, a sinus rhythm of 150 bpm
was recorded several times for 5 — 20 seconds.
On August 31, 1986 there was an intraperitoneal
administration of 10 g betamethyldigoxin and
2 mg propafenon. The atrial flutter persisted de-
spite these measures, but on August 30, 1986
there was a constant 2:1 conduction block so
that the ventricular frequency was 150 bpm. The
color Doppler-echocardiography demonstrated
better contractility with only slight regurgitation
in the AV-valve area; the fetus became more lively,
the effusion no longer increased. Unfortunately,
because of the undesirable sympathomimetic car-
diac effects in this case, high-dose intravenous
tocolysis (max. 4 g fenoterol/minute) had to be
given from the day of admission because of early
cervical dilatation. When the tocolysis was re-
duced, there was silent cervical dilatation to 5 cms
in diameter. On September 6, 1986 (34th week
gestation) immediately after prepartal aspiration
of 300 ml ascites the delivery was carried out
by cesarean section: hydropic female infant, 3650
grams, immediate intubation and respiration. Ap-
gar score 2/4/7/7 at 1, 3, 5 and 10 minutes (digoxin
concentration 17 hours after the last drug adminis-
tration: maternal blood: 1.4 ng/ml; umbilical vein
blood: 1.2 ng/ml). Following delivery and anti-
arrthythmic therapy, there was cardioversion of
the neonate, sinus rhythm in a normal frequency
and subsequent reduction of the ascites and skin
edema. Later thereby, discontinuation of drugs
and discharge. Through January 9,1987 there has
been normal growth and development.
3 Discussion
Intrauterine therapy of fetal tachyarrhythmia has
out up to now been carried by the transplacental
route. Antiarrhythmic agents administered to the
mother reached the fetal compartments through
the placenta. Agents of first choice with good
.placental crossing ability are the cardiac glycosi-
des, which have not only an antiarrhythmic but
also an positive inotropic effect. Also used are
verapamil, propanolol, propafenon and in some
cases, quinidine, procainamide, amiodarone and
flecainide. On the one hand, when the latter anti-
arrhythmic agents are used, undesirable effects
in the fetus may occur, particularly with already
existing cardiac insufficiency due to the negative
inotropic effects of some of these antiarrhythmic
agents. It is still relatively unclear whether and to
what extent these drugs cross the placenta [1, 2,
5, 11, 12, 13].
Successful cardioversion of fetal tachyarrhythmia
by transplacental administration of anti-
arrhythmic agents has been described frequently.
In the cases of advanced cardiac decompensation
with the signs of severe non-immune hydrops fet-
alis, it would appear that this therapy seldom
leads to constant cardioversion and remission of
the fluid accumulation, even with high dose drug
therapy. This could be due to the following: The
early appearance of undesirable side effects from
the antiarrthythmic agents to the mother which
would not permit the dose to be increased; the
transplacental crossing of the drugs from the ma-
ternal to the fetal compartments is hampered, viz.
due to the abnormal state of the fetal circulation
in cardiac insufficiency which may also lead to
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placental changes resulting in hydrops placentae;
the insufficient „sick" fetal heart is a poor re-
sponder to the antiarrhythmic therapy compared
to that of an unaffected heart; in some cases, a
sufficient drug level may not be reached if the fetus
has already died prior to therapy; antiarrhythmic
agents which are normally efficacious do not reach
an effective level in the fetal compartments since
they cannot or only cross the placenta in a limited
manner.
All of these considerations make it seem favorable
to carry out direct antiarrhythmic treatment of
the fetus at least in the case of manifest heart
failure. In the therapy of rhesus incompatibility
the direct treatment of the fetus in the form of
intraperitoneal blood transfusion has been re-
ported by LILEY [10] in 1963. HANSMANN and
LANG [6] did this for the first time using ultra-
sound monitoring in 1972. At present ultrasound
guided direct interventions in the fetus are so
highly developed that, for example, fetal effusion
can be aspirated and fetal vessels punctured for
diagnostic blood analysis or intravascular transfu-
sion and exchange transfusion [3, 4, 7, 8].
Intravascular administration of antiarrhythmic
agents can be carried out by ultrasound guided
injections in the umbilical vein. This is technically
difficult and in individual cases impossible, de-
pending on the unfavorable location of the fetus
and the placenta or the umbilical cord connection.
In fetuses eligible for antiarrhythmic direct ther-
apy with non-immune hydrops fetalis, there is
always some ascites, so that an intraperitoneal
administration of anti-arrthythmic agents is tech-
nically simple and can be easily repeated. In our
first case, using concomitant high dose transpla-
cental therapy, sustained periods of sinus rhythm
of varying duration were observed 5 — 15 minutes
after 12 intraperitoneal administrations of anti-
arrhythmic agents. This it may be assumed that
the resorption of drugs from the ascites takes
place rapidly. In the second case, 8 minutes afer
injection, there was only a very brief period of
sinus rhythm with a following flutter. Due to the
apparently very rapid resorption of the drugs from
the ascites we did not substantially exceed the
dosing amounts for intravenous injections in the
intraperitoneal administration of antiarrhythmic
agents, in order to avoid fatal intrauterine effects
which are difficult to monitor since we were un-
aware of the concentrations previously reached by
the transplacental route in the fetal compartments.
4 Conclusion
Indications for direct administration of anti-
arrhythmic drup directly into the peritoneal fluid
of the fetus, in addition to transplacental therapy,
must include fetal emergency states due to non-
immune hydrops fetalis secondary to tachy-
arrhythmia. By doing this, it is possible to reach
high concentrations of antiarrhythmic agents in
the fetal compartments more rapidly than by the
transplacental route particularly in the case of
drugs that only limitedly cross the placenta. Intra-
peritoneal therapy is also optimal therapy when
no further increase in the dose of oral medication
is possible due to side effects which might jeopard-
ize the health of the mother. In such case, intraper-
itoneal administration of antiarrhythmic agents is
an effective, technically simple, option which can
be repeated at short intervals.
Summary
In cases of fetal tachyarrhythmia with congestive heart
failure accompanied by signs of non-immune hydrops
fetalis, the transplacental treatment of the fetus with
antiarrhythmic agents by administration of drugs to the
mother is only rarely successful. In the two cases re-
ported, the cardioversion of a supraventricular tachycar-
dia to a sinus rhythm or a constant 2 :1 AV conduction
block to a 1 :1 AV conduction with atrial flutter could
only be achieved after additional antiarrhythmic treat-
ment directly administered to the fetus using ultrasound
guidance. Drugs used include: beta-methyldigoxin, ver-
apamil, propafenon. and they were administered accord-
ing to the dosing amounts for intravascular injections.
This was carried out 12 times in case 1 by the intraper-
itoneal route into the fetal ascites and twice in case 2.
This led in both cases to varying durations of a sustained
sinus rhythm after 5 — 15 minutes. This technically rela-
tively simple procedure affords the option of rapidly
achieving high concentrations, even when anti-
arrhythmic agents are administered which do not ad-
equately cross the placenta. This direct treatment is
indicated in cases of tachyarrhythmia with advanced
signs of non-immune hydrops fetalis as a supplement to
the high-dose transplacental therapy using anti-
arrhythmic agents.
Keywords: Fetal Doppler echocardiography, fetal echocardiography, fetal heart arrhythmia, fetal heart failure,
fetal tachyarrhythmia, fetus, intrauterine therapy, non-immune hydrops fetalis, prenatal diagnosis,
ultrasonography.
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Zusammenfassung
Intrauterine Therapie fetaler Tachyarrhythmien: Intrape-
ritoneale Antiarrhythmikagabe an den Feten bei fetalen
Tachyarrhythmien mit schwerem Hydrops fetalis
Bei Vorliegen eines schweren nicht-immunologisch be-
dingten Hydrops fetalis infolge einer fetalen Herzinsuffi-
zienz aufgrund fetaler Tachyarrythmien ist die alleinige
transplazentare antiarrhythmische Behandlung des Fe-
ten via Mutter nur selten erfolgreich. In den beiden
beschriebenen Fällen konnte die Kardioversion einer
supraventrikulären Tachykardie in einen Sinusrhythmus
bzw. die Überführung in eine konstante 2 : l AV-Über-
leitung bei zuvor vorhandender l : l AV-Überleitung bei
Vorhofflattern nur durch eine zusätzliche Direktbehand-
lung des Feten erreicht werden. Hierbei wurden die
Antiarrythmika (Beta-Methyldigoxin, Verapamil, Pro-
pafenon) Ultraschall-gesteuert intraperitoneal in den fe-
talen Ascites appliziert — gemäß der für die intravasku-
läre Injektion üblichen, gewichtsbezogenen Dosierungs-
richtlinien. Dieser Eingriff wurde bei einem Feten (su-
praventrikuläre Tachykardie) zwölfmal, bei dem anderen
(Vorhofflattern) zweimal durchgeführt, wonach 5 — 15
Minuten später unterschiedlich lang anhaltende Sinus-
rhythmen auftraten. Diese technisch relativ einfache und
daher oft wiederholbare intraperitoneale Antiarrhythmi-
kagabe bietet die Möglichkeit, schnell hohe Antiarrhyth-
mikakonzentrationen in den fetalen Kompartimenten
zu erreichen, auch wenn die gewählten Medikamente
schlecht plazentagängig sind. Indiziert ist diese Behand-
lung bei tachyarrhythmischen Feten mit schwerem Hy-
drops fetalis, zusätzlich zur üblichen hochdosierten
transplazentaren Antiarrhythmikagabe. Sie scheint die
Prognose auch für diese schwerkranken Kinder zu ver-
bessern.
Schlüsselwörter: Fet, fetale Doppler-Echokardiographie, fetale Echokardiographie, fetale Herzinsuffizienz, fetale
Herzrhythmusstörung, fetale Tachyarrhythmie, intrauterine Therapie, nicht-immunologischer Hy-
drops fetalis, pränatale Diagnostik, Ultraschall.
Resume
Traitement in utero des tachyarythmies fatales: Injection
fetale intraperitoneale de medicaments anti-arythmiques
lors de tachyarythmies fetales s'accompagnant d'hydrops
fetalis severe
La traitement transplacentaire du foetus par des agents
antiarythmiques grace a l'administration de medica-
ments ä la mere n'est que rarement couronne de succes
en cas de tachyarythmies foetales avec defaillance cardia-
que congestive s'accompagnant de signes d'hydrops
foetalis non immunologique. Dans les deux cas decrits
la cardioversion d'une tachycardie supraventriculaire en
rythme sinusal ou en conduction AV 2/1 constante alors
qu'il existait avant une conduction AV 1/1 avec flutter
auriculaire n'a pu etre obtenue qu'apres traitement anti-
arythmique additionel direct au foetus en utilisant une
surveillance echographique et des medicaments (beta-
Mots-cles: Arythmie cardiaque foetale, defaillance cardiaque foetale, diagnostic prenatal, echocardiographie
Doppler foetale, echocardiographie foetale, echögraphie, foetus, hydrops foetalis non immunologique,
traitement in utero, tachyarythmie foetale.
methyldigoxine, verapamil, propafenon) injectes aux do-
ses utilisees pour la voie intra-veineuse. Ce protocole a
ete realise 12 fois chez le premier foetus par voie intra-
peritoneale au niveau de l'ascite foetale et deux fois chez
le second aboutissant chez les deux foetus a des periodes
variables de rhythme sinusal continu au bout de 5 ä 15
minutes. Cette methodologie, techniquement relative-
ment simple, soutient l'option de concentrations elevees
rapidement obtenues, meme lorsque les agents antiaryth-
miques administres ne traversent pas suffisement le pla-
centa. Le traitement direct est indique dans les cas de
tachyarythmies s'accompagnant de signes graves
d'hydrops foetalis non immunologique comme comple-
ment d'une therapeutique a haute dose par voie transpla-
centaire utilisant des agents antiarythmiques.
Medications used in this study:
Beta-Methyldigoxin (Lanitop®, Boehringer AG, Mann-
heim, FRG)
Verapamil (Isoptin®, Knoll AG, Ludwigshafen, FRG)
Propafenon (Rhythmonorm®, Knoll AG, Ludwigsha-
fen, FRG)
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